Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,401 to 4,420 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Prior CD Decision App (PCDDA) vs Usual Care - No App: 3rd or 4th Degree Lacerations | 16 of 720 12 of 723 | 0.6 points -0.9 to 2.1 | 1,443 | NCT02646423 Effect of a Patient-Centered Decision App on TOLAC |
| Prior CD Decision App (PCDDA) vs Usual Care - No App: Maternal Major Morbidity | 19 of 720 23 of 723 | -0.5 points -2.4 to 1.2 | 1,443 | NCT02646423 Effect of a Patient-Centered Decision App on TOLAC |
| Prior CD Decision App (PCDDA) vs Usual Care - No App: Neonatal Intensive Care Unit (NICU) Admission | 98 of 720 87 of 722 | 1.6 points -1.9 to 5.0 | 1,442 | NCT02646423 Effect of a Patient-Centered Decision App on TOLAC |
| Total Hip Arthroplasty vs Hemi-arthroplasty: deaths from any cause | 103 of 718 95 of 723 | 1.2 points -2.4 to 4.8 | 1,441 | NCT00556842 Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Adults With Displaced Hip Fractures |
| Total Hip Arthroplasty vs Hemiarthroplasty: Number of Participants With Functional Mobility Problems | 210 of 718 206 of 723 | 0.8 points -3.9 to 5.4 | 1,441 | NCT00556842 Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Adults With Displaced Hip Fractures |
| Total Hip Arthroplasty vs Hemi-arthroplasty: Number of Participants With Revision Surgery | 57 of 718 60 of 723 | -0.4 points -3.2 to 2.5 | 1,441 | NCT00556842 Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Adults With Displaced Hip Fractures |
| Total Hip Arthroplasty vs Hemi-arthroplasty: serious adverse events | 300 of 718 265 of 723 | 5.1 points 0.1 to 10.1 | 1,441 | NCT00556842 Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Adults With Displaced Hip Fractures |
| EP2006: Any CIN/FN-related Chemotherapy Disturbance vs EP2006: No CIN/FN-related Chemotherapy Disturbance: Number of Participants With Cancer-related Mortality by Any CIN/FN-related Chemotherapy Disturbance | 2 of 138 33 of 1,303 | -1.1 points -2.5 to 2.7 | 1,441 | NCT01459653 Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor |
| EP2006: Any Grade 4 CIN/FN vs EP2006: No Grade 4 CIN/FN: Number of Participants With Cancer-related Mortality by Any/no Grade 4 CIN or FN | 6 of 221 29 of 1,220 | 0.3 points -1.4 to 3.5 | 1,441 | NCT01459653 Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor |
| Prior CD Decision App (PCDDA) vs Usual Care - No App: Maternal Minor Morbidity | 36 of 719 36 of 722 | 0.0 points -2.3 to 2.3 | 1,441 | NCT02646423 Effect of a Patient-Centered Decision App on TOLAC |
| Regimen A vs Regimen B: serious adverse events | 10 of 112 785 of 1,328 | -50.2 points -55.0 to -42.9 | 1,440 | NCT00026312 Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma |
| Subcutaneous Abatacept vs Intravenous Abatacept: Double-blind Period: Number of Participants Achieving Clinically Meaningful HAQ-DI Response at Day 169 | 483 of 729 442 of 711 | 4.1 points -0.9 to 9.0 | 1,440 | NCT00559585 Methotrexate-Inadequate Response Study |
| Prior CD Decision App (PCDDA) vs Usual Care - No App: Neonatal Respiratory Morbidity | 67 of 719 68 of 721 | -0.1 points -3.1 to 2.9 | 1,440 | NCT02646423 Effect of a Patient-Centered Decision App on TOLAC |
| Hyperinsulinemic-normoglycemic Clamp vs Insulin at the Standard of Care Levels: Any Major Morbidity/30-day Mortality | 46 of 709 82 of 730 | -4.7 points -7.7 to -1.8 | 1,439 | NCT00524472 Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery |
| Hyperinsulinemic-normoglycemic Clamp vs Insulin at the Standard of Care Levels: Post Operative Atrial Fibrillation | 209 of 709 235 of 730 | -2.7 points -7.5 to 2.1 | 1,439 | NCT00524472 Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery |
| Hyperinsulinemic-normoglycemic Clamp vs Insulin at the Standard of Care Levels: a Composite of Minor Postoperative Complications | 200 of 709 237 of 730 | -4.3 points -9.0 to 0.5 | 1,439 | NCT00524472 Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery |
| Hyperinsulinemic-normoglycemic Clamp vs Insulin at the Standard of Care Levels: deaths from any cause | 32 of 709 22 of 730 | 1.5 points -0.5 to 3.6 | 1,439 | NCT00524472 Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery |
| Hyperinsulinemic-normoglycemic Clamp vs Insulin at the Standard of Care Levels: serious adverse events | 18 of 709 27 of 730 | -1.2 points -3.0 to 0.7 | 1,439 | NCT00524472 Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery |
| Drug Users vs Non-drug Users: The Prevalence of Superficial and Cutaneous Fungal Infections Among Drug and Non-Drug Users | 73 of 718 62 of 718 | 1.5 points -1.5 to 4.6 | 1,436 | NCT02681458 Superficial and Cutaneous Fungal Infections Among Drug-users in Northeast Region of Iran |
| Distress Screening vs No Screening: Number of Participants Offered and Screened for Distress | 596 of 744 3 of 692 | 79.7 points 76.5 to 82.4 | 1,436 | NCT02941614 Implementing Systematic Distress Screening in Breast Cancer |
Code
curl "https://conductscience.org/api/comparisons/v1?page=221"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=221
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02646423-1b635b2c",
"title": "Prior CD Decision App (PCDDA) vs Usual Care - No App: 3rd or 4th Degree Lacerations",
"summary": "16 of 720 against 12 of 723; risk difference 0.6 points, 95% interval -0.9 to 2.1; NCT02646423, Effect of a Patient-Centered Decision App on TOLAC",
"record": "/library/comparisons/NCT02646423-1b635b2c",
"nct_id": "NCT02646423",
"kind": "outcome",
"participants": 1443,
"risk_difference": {
"value": 0.00562471184877824,
"lower": -0.009233205775438229,
"upper": 0.020929080954219855
},
"group_1": "16 of 720",
"group_2": "12 of 723",
"difference": "0.6 points",
"interval": "-0.9 to 2.1",
"trial_title": "Effect of a Patient-Centered Decision App on TOLAC"
},
{
"id": "NCT02646423-45065188",
"title": "Prior CD Decision App (PCDDA) vs Usual Care - No App: Maternal Major Morbidity",
"summary": "19 of 720 against 23 of 723; risk difference -0.5 points, 95% interval -2.4 to 1.2; NCT02646423, Effect of a Patient-Centered Decision App on TOLAC",
"record": "/library/comparisons/NCT02646423-45065188",
"nct_id": "NCT02646423",
"kind": "outcome",
"participants": 1443,
"risk_difference": {
"value": -0.005423005993545411,
"lower": -0.023541704636688515,
"upper": 0.012458285505082073
},
"group_1": "19 of 720",
"group_2": "23 of 723",
"difference": "-0.5 points",
"interval": "-2.4 to 1.2",
"trial_title": "Effect of a Patient-Centered Decision App on TOLAC"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=222",
"request_id": "KXwgErVnOjBZ1rk4"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant